Followers | 927 |
Posts | 82612 |
Boards Moderated | 2 |
Alias Born | 10/31/2008 |
Tuesday, April 25, 2023 12:02:17 PM
Buy and Sell stocks at your own risk. What I say in my posts are strictly my opinion.
Recent ALLR News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/30/2024 08:05:53 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 08/29/2024 09:57:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:55:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 09:24:15 PM
- Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting • GlobeNewswire Inc. • 07/26/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/26/2024 10:04:13 AM
- Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares • GlobeNewswire Inc. • 07/24/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:05:17 PM
- Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives • GlobeNewswire Inc. • 07/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 10:03:17 AM
- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:54:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 12:15:26 PM
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 05/20/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 08:08:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:45:38 PM
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 03:21:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:47:15 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/08/2024 08:05:18 PM
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock • GlobeNewswire Inc. • 05/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:29:16 PM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM